reading time

SN Share Price

In 2020, Smith & Nephew plc reported revenue of $4.6 billion, which represented a decline of 12.1% compared to the previous year. The decline was primarily due to the impact of the COVID-19 pandemic, which resulted in delayed elective surgeries and reduced demand for specific medical devices and products. However, the company’s revenue decline was partially offset by growth in its Advanced Wound Bioactives and Sports Medicine franchises.

[lwptoc]

SN Share Price

Smith & Nephew plc is a medical technology company that designs, manufactures, and sells medical devices and equipment for surgical and wound care markets. The company is publicly traded on the London Stock Exchange (LSE) under the ticker symbol SN and listed on the New York Stock Exchange (NYSE) under the same ticker symbol. As of this post, SN’s Share Price is at 1,280.35

Smith & Nephew plc had a market capitalisation of around £17.4 billion (approximately USD 23.7 billion), and its stock price on the LSE was trading at around £13.86 per share.

SN Share Price

Brief History of SN Share Price

Smith & Nephew plc has a long and rich history of over 160 years. The company was founded in 1856 by Thomas James Smith, who opened a small pharmacy in Hull, England, where he sold his brand of surgical dressings. In 1937, Smith & Nephew merged with a rival company, British Tabulating Machine Company (BTM), to form Smiths Industries.

In 1999, Smiths Industries demerged its healthcare division, which became Smith & Nephew plc. Since then, the company has focused on developing and manufacturing medical devices and equipment for the global surgical and wound care markets. Today, Smith & Nephew plc is one of the world’s leading medical technology companies, with operations in more than 100 countries and a broad portfolio of products across multiple medical specialities.

Over the years, Smith & Nephew plc has undergone numerous acquisitions and divestitures to expand its product portfolio and geographic reach. Some notable acquisitions include the orthopaedic businesses of the Swiss company Mathys Medical and US-based ArthroCare Corporation. In addition, the company has also divested non-core businesses, such as its gynaecology and urology businesses, to focus on its core areas of expertise.

Overall, Smith & Nephew plc has a long history of innovation and leadership in the medical technology industry and continues to invest in research and development to drive future growth and success.

Advantages of Investing in SN Share Price

SN Share Price is a leading player in the global medical technology industry, with a strong market position in several key product categories, such as orthopaedics, sports medicine, and wound care. This market position gives the company a competitive advantage and helps to support its long-term growth prospects.

The company has a broad portfolio of products across multiple medical specialities, which helps to mitigate risk and provides a stable source of revenue. The company’s products include joint replacement implants, sports medicine devices, wound care products, and advanced surgical technologies.

SN Share Price has a global presence, with operations in over 100 countries, which provides geographic diversity and exposure to multiple economies. This diversification helps to reduce risk and provides a stable source of revenue.

SN Share Price has a solid financial track record, consistent revenue and earnings growth over the past several years. The company has also demonstrated strong cash flow generation and has a solid balance sheet, which could support future growth initiatives.

Main Competitors of SN Share Price

  1. Johnson & Johnson (J&J). J&J is a multinational medical device, pharmaceutical, and consumer goods company. The company’s medical devices division competes with Smith & Nephew plc in orthopaedics, sports medicine, and wound care.
  2. Stryker Corporation. Stryker is a leading global medical technology company specialising in orthopaedics, medical and surgical, neurotechnology, and spine products. The company competes with Smith & Nephew plc in joint replacement implants, sports medicine devices, and advanced surgical technologies.
  3. Medtronic plc. Medtronic is a multinational medical technology company that develops and manufactures medical devices across various specialities, including cardiac and vascular, minimally invasive, and restorative therapies. In addition, the company competes with Smith & Nephew plc in wound care, joint replacement, and sports medicine.
  4. Zimmer Biomet Holdings, Inc. Zimmer Biomet is a global medical technology company specialising in musculoskeletal healthcare. The company’s products include joint replacement, trauma, sports medicine, spine, and dental implants. Zimmer Biomet competes with Smith & Nephew plc in joint replacement implants and sports medicine devices.
  5. ConvaTec Group plc. ConvaTec is a global medical products and technologies company specialising in advanced wound care, ostomy care, continence and critical care, and infusion devices. The company competes with Smith & Nephew plc in wound care products.

The Best Copytrading Platform

eToro UK
★★★★★
Minimum deposit 200 USD
Regulated in Europe
Trade selections Forex, Crypto, Stocks, Commodities, ETFs, Indices
  • Zero Commissions on Trades

  • CopyPortfolios/Copytrade Feature

  • Ask Experts Questions

  • Wide Range of Stocks

Conclusion

Despite the revenue decline, Smith & Nephew plc reported a net profit of $298 million in 2020, up from $156 million in 2019. The increase in net profit was due to reduced expenses, including a decrease in research and development spending and lower restructuring costs.

In terms of its outlook, Smith & Nephew plc has expressed confidence in its ability to return to growth in the coming years. The company has a strong pipeline of new products and technologies in development and is focusing on expanding its presence in high-growth markets, such as China and India.

FAQ

FAQ: SN Share Price

What is the historic performance of Smith & Nephew plc stock?

Over the past ten years, Smith & Nephew plc's stock has generally performed well, with periods of volatility due to various economic and industry factors. As of September 2021, the company's stock had a market capitalisation of approximately $21 billion and was trading on the London Stock Exchange (LSE) under the ticker SN.L.

Between April 2011 and September 2021, Smith & Nephew plc's stock price has ranged from a low of around £5.50 per share to a high of around £23 per share. The stock price has generally trended upward over this period, with some periods of volatility due to macroeconomic factors such as the COVID-19 pandemic.

Does Smith & Nephew plc pay dividends to its stockholders?

Yes, Smith & Nephew plc pays dividends to its stockholders. The company has a record of paying dividends for many years, with a current policy of paying out 40-50% of its earnings in the form of dividends.

Who are the target investors of Smith & Nephew plc?

As a publicly traded company, Smith & Nephew plc's shares are available for purchase by any investor through a stockbroker or an online trading platform. However, the company may target specific types of investors in its marketing and outreach efforts.

Smith & Nephew plc is a global medical technology company that develops and sells products and services to healthcare providers and patients. As such, the company may target investors interested in the healthcare sector and have a long-term investment horizon.

In addition, Smith & Nephew plc may also target investors interested in companies with a strong track record of innovation, research and development, and new product launches. The company invests heavily in R&D and has a broad range of products and services across multiple healthcare markets, including orthopaedics, sports medicine, and wound care.

Rate this post
Simon Williams
Latest posts by Simon Williams (see all)